Initial Antituberculous Regimen with Better Drug Penetration into Cerebrospinal Fluid Reduces Mortality in HIV Infected Patients with Tuberculous Meningitis: Data from an HIV Observational Cohort Study

Gerardo Alvarez-Uria, Manoranjan Midde, Raghavakalyan Pakam, Praveen Kumar Naik, Gerardo Alvarez-Uria, Manoranjan Midde, Raghavakalyan Pakam, Praveen Kumar Naik

Abstract

Tuberculous meningitis (TM) is the deadliest form of tuberculosis. Nearly two-thirds of HIV infected patients with TM die, and most deaths occur within one month. Current treatment of TM involves the use of drugs with poor penetration into the cerebro-spinal fluid (CSF). In this study, we present the mortality before and after implementing a new antituberculous regimen (ATR) with a higher drug penetration in CSF than the standard ATR during the initial treatment of TM in an HIV cohort study. The new ATR included levofloxacin, ethionamide, pyrazinamide, and a double dose of rifampicin and isoniazid and was given for a median of 7 days (interquartile range 6-9). The new ATR was associated with an absolute 21.5% (95% confidence interval (CI), 7.3-35.7) reduction in mortality at 12 months. In multivariable analysis, independent factors associated with mortality were the use of the standard ATR versus the new ATR (hazard ratio 2.05; 95% CI, 1.2-3.5), not being on antiretroviral therapy, low CD4 lymphocyte counts, and low serum albumin levels. Our findings suggest that an intensified initial ATR, which likely results in higher concentrations of active drugs in CSF, has a beneficial effect on the survival of HIV-related TM.

Figures

Figure 1
Figure 1
Kaplan-Meier survival estimates by the initial antituberculous regimen of 203 HIV patients with tuberculous meningitis. iATR, initial antituberculous regimen.
Figure 2
Figure 2
Kaplan-Meier survival estimates by baseline serum albumin levels (a), CD4 lymphocyte count (b), and duration of antiretroviral therapy (ART) of 203 HIV patients with tuberculous meningitis (c). ART, antiretroviral therapy; TB, tuberculous.

References

    1. World Health Organization. Global tuberculosis control. 2012, .
    1. Brancusi F, Farrar J, Heemskerk D. Tuberculous meningitis in adults: a review of a decade of developments focusing on prognostic factors for outcome. Future Microbiol. 2012;7:1101–1116.
    1. Schutz C, Meintjes G, Almajid F, Wilkinson RJ, Pozniak A. Clinical management of tuberculosis and HIV-1 co-infection. European Respiratory Journal. 2010;36(6):1460–1481.
    1. Alvarez-Uria G, Naik PK, Pakam R, Bachu L. Natural history and factors associated with early and delayed mortality in HIV infected patients treated of tuberculosis under directly observed treatment short course (DOTS) strategy: a prospective cohort study in India. Interdisciplinary Perspectives on Infectious Diseases. 2012;2012:9 pages.502012
    1. Thwaites G, Fisher M, Hemingway C, Scott G, Solomon T, Innes J. British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children. Journal of Infection. 2009;59(3):167–187.
    1. World Health Organization. Treatment of Tuberculosis: Guidelines for National Programmes. 4th edition. 2009.
    1. Centers for Disease Control and Prevention. National Institutes of Health, HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for the Prevention and treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents, 2013, .
    1. Donald PR. Cerebrospinal fluid concentrations of antituberculosis agents in adults and children. Tuberculosis. 2010;90:279–292.
    1. Heemskerk D, Day J, Chau TTH, et al. Intensified treatment with high dose Rifampicin and Levofloxacin compared to standard treatment for adult patients with Tuberculous Meningitis (TBM-IT): protocol for a randomized controlled trial. Trials. 2011;12, article 25
    1. Thwaites GE, Bhavnani SM, Chau TTH, et al. Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis. Antimicrob Agents Chemother. 2011;55:3244–3253.
    1. Ruslami R, Ganiem AR, Dian S, et al. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. The Lancet Infectious Diseases. 2013;13:27–35.
    1. Torok ME, Chau TTH, Mai PP, et al. Clinical and microbiological features of HIV-associated tuberculous meningitis in Vietnamese adults. PLoS ONE. 2008;3(3, article e1772)
    1. Alvarez-Uria G, Midde M, Pakam R, Naik PK. Gender differences, routes of transmission, socio-demographic characteristics and prevalence of HIV related infections of adults and children in an HIV cohort from a rural district of India. Infectious Disease Reports. 2012;4, article e19
    1. Alvarez-Uria G, Midde M, Pakam R, et al. Factors associated with late presentation of HIV and estimation of antiretroviral treatment need according to CD4 lymphocyte count in a resource-limited setting: data from an HIV Cohort Study in India. Interdisciplinary Perspectives on Infectious Diseases. 2012;2012:7 pages.293795
    1. Marais S, Thwaites G, Schoeman JF, et al. Tuberculous meningitis: a uniform case definition for use in clinical research. The Lancet Infectious Diseases. 2010;10:803–812.
    1. Marx GE, Chan ED. Tuberculous meningitis: diagnosis and treatment overview. Tuberculosis Research and Treatment. 2011;2011:9 pages.798764
    1. Donald PR, Diacon AH. The early bactericidal activity of anti-tuberculosis drugs: a literature review. Tuberculosis. 2008;88(supplement 1):S75–S83.
    1. WHO. Treatment of Tuberculosis: Guidelines for National Programmes. 3rd edition. 2003. WHO/CDS/TB/2003.313, .
    1. Alvarez-Uria G, Midde M, Naik PK. Socio-demographic risk factors associated with HIV infection in patients seeking medical advice in a rural hospital of India. Journal of Public Health Research. 2012;1, article e14
    1. Kleinbaum DG, Klein M. Survival Analysis, A Self-Learning Text. 2nd edition. Springer; 2005.
    1. Royston P. Multiple imputation of missing values: further update of ice, with an emphasis on categorical variables. Stata Journal. 2009;9(3):466–477.
    1. Pepper DJ, Marais S, Maartens G, et al. Neurologic manifestations of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome: a case series. Clinical Infectious Diseases. 2009;48(11):e96–e107.
    1. Cecchini D, Ambrosioni J, Brezzo C, et al. Tuberculous meningitis in HIV-infected patients: drug susceptibility and clinical outcome. AIDS. 2007;21(3):373–374.
    1. Sudfeld CR, Isanaka S, Aboud S, et al. Association of serum albumin concentration with mortality, morbidity, CD4 T-cell reconstitution among tanzanians initiating antiretroviral therapy. The Journal of Infectious Diseases. 2013;207:1370–1378.
    1. Tabarsi P, Chitsaz E, Moradi A, et al. Treatment outcome, mortality and their predictors among HIV-associated tuberculosis patients. International Journal of STD & AIDS. 2012;23:e1–e4.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir